ARTICLE | Company News
AstraZeneca adds oncolytic virus option through Transgene deal
May 2, 2019 5:31 AM UTC
AstraZeneca is taking another look at oncolytic viruses through an option deal with French biotech Transgene.
On Thursday, the partners said AstraZeneca plc (LSE:AZN; NYSE:AZN) would receive an exclusive option to co-develop and commercialize five armed oncolytic viruses generated by the Invir.IO oncolytic virus platform of Transgene S.A. (Euronext:TNG)...